Remdesivir is DEADLY, causes acute renal (nephrotoxicity) & liver failure: why is FDA, NIH, Health Canada etc. health officials, doctors, hospitals pushing this on patients? knowing it kills! O Gérard
we detected a statistically significant pharmacovigilance signal of nephrotoxicity associated with remdesivir, deserving a thorough qualitative assessment of all available data.
Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database
https://pubmed.ncbi.nlm.nih.gov/33340409/
‘Remdesivir is approved for emergency use by the US Food and Drug Administration (FDA) and authorized conditionally by the European Medicines Agency (EMA) for patients with coronavirus disease 2019 (COVID-19). Its benefit-risk ratio is still being explored because data in the field are rather scant.
A decrease of the creatinine clearance associated with remdesivir has been inconstantly reported in clinical trials with unclear relevance. Despite these uncertainties, we searched for a potential signal of acute renal failure (ARF) in pharmacovigilance postmarketing data.
An analysis of the international pharmacovigilance postmarketing databases (VigiBase) of the World Health Organization (WHO) was performed, using two disproportionality methods. Reporting odds ratio (ROR) compared the number of ARF cases reported with remdesivir, with those reported with other drugs prescribed in comparable situations of COVID-19 (hydroxychloroquine, tocilizumab, and lopinavir/ritonavir).
The combination of the terms "acute renal failure" and "remdesivir" yielded a statistically significant disproportionality signal with 138 observed cases instead of the 9 expected. ROR of ARF with remdesivir was 20-fold (20.3; confidence interval 0.95 [15.7-26.3], P < 0.0001]) that of comparative drugs.
Based on ARF cases reported in VigiBase, and despite the caveats inherent to COVID-19 circumstances, we detected a statistically significant pharmacovigilance signal of nephrotoxicity associated with remdesivir, deserving a thorough qualitative assessment of all available data. Meanwhile, as recommended in its Summary of Product Characteristics, assessment of patients with COVID-19 renal function should prevail before and during treatment with remdesivir in COVID-19.’
In February 2022 my unvaccinated, healthy 71-year old husband was diagnosed with a DVT in his left leg and two PEs. We were terrified at his shortness of breath and even more terrified that we had no choice but to go to the hospital. At the hospital he was swabbed for flu and covid. He tested positive for covid (although he’d had a bad case in November 2021). Our small town hospital ambulanced him to a hospital in a city 3 hours away because they thought the blood clots might require surgery and they had no vascular surgeon on staff. Even though I called the city hospital and begged them to let me be with him after I traveled there, they gently refused because of his covid diagnosis. I’m happy to report that he had excellent care at both hospitals, thank the Lord, but the night nurse told him she would return shortly to give him a shot of remdesivir. Thankfully through people like Dr Alexander we knew the dangers. He told the nurse, “I’m going to refuse that shot. If my wife was here she’d be able to tell you why, but anyhow, I refuse to take it.” She said that it was hospital protocol because he’d tested positive for covid , but she backed right off. The information from doctors like Dr Alexander has been life-saving. Thank you.
Please be aware there are 2 names. Hospitals are now using the brand name Veklury as people get wise to Remdisivir.
Generic Name: Remdesivir (RDV)
Brand Name: Veklury.